Liquidseq Breast & Ovarian Cancer Panel [93 genes]
About Liquidseq Breast & Ovarian Cancer Panel [93 genes]
| Field | Value |
|---|---|
| Also Known As | Liquidseq Breast & Ovarian Cancer Panel (93 Genes), Liquid Biopsy Breast & Ovarian Panel, Circulating Tumour DNA (ctDNA) Breast and Ovarian Cancer Panel |
| Sample Type | Peripheral venous blood (collected in specialised cell-free DNA preservation tubes) |
| Fasting Required | No fasting required |
| Report Time | 30 days |
| Recommended For | Adults with suspected or confirmed breast or ovarian cancer; patients requiring molecular profiling for treatment planning |
| Price | Starting at ₹72,000 |
What is a Liquidseq Breast & Ovarian Cancer Panel [93 genes]?
The Liquidseq Breast & Ovarian Cancer Panel is a liquid biopsy test that analyses circulating tumour DNA (ctDNA) — tiny fragments of tumour DNA found in the blood. It examines 93 genes linked to breast and ovarian cancers to detect mutations that may guide treatment decisions. The test is typically ordered by an oncologist for patients with suspected or confirmed breast or ovarian cancer. It is also known as the Liquid Biopsy Breast & Ovarian Panel or Circulating Tumour DNA Breast and Ovarian Cancer Panel.
What Does a Liquidseq Breast & Ovarian Cancer Panel Measure?
This panel scans 93 genes for mutations relevant to breast and ovarian cancers. The following are key genes included in the analysis:
| Gene | Role |
|---|---|
| ACVR1B | Involved in cell growth and differentiation signalling |
| AKT1 | Part of the mTOR signalling pathway; mutations linked to breast, ovarian, and colorectal cancers |
| APC | The definitive tumour suppressor gene for colorectal cancer (specifically associated with Familial Adenomatous Polyposis, or FAP). While somatic APC alterations can occasionally appear as random, secondary mutations in various advanced solid tumors, it is not a major driver or significantly altered gene in breast cancer |
| AR (Androgen Receptor) | Expressed in breast tissue and tumours; linked to treatment response |
| ATM | Central to DNA repair and cell division, mutations raise risk of breast and ovarian cancers |
| ATR | Activates key tumour suppressors including BRCA1 and p53; a candidate gene for cancer susceptibility |
| BRCA1 / BRCA2 | Well-established hereditary breast and ovarian cancer genes |
| TP53 | A major tumour suppressor gene mutated in many cancer types |
| PIK3CA | Commonly mutated in breast cancer; relevant for targeted therapy eligibility |
| PTEN | Tumour suppressor associated with breast and ovarian cancer risk |
| PALB2, RAD51C, RAD51D | DNA repair genes linked to hereditary cancer syndromes |
| MLH1, MSH2, MSH6, PMS2 | Mismatch repair genes; mutations associated with Lynch syndrome |
| CDK4, CDK6 | Cell cycle regulators targeted by approved breast cancer therapies |
| ERBB2 (HER2) | Overexpression or mutation drives HER2-positive breast cancer |
| ESR1 | Oestrogen receptor gene; mutations associated with hormone therapy resistance |
The test reports results qualitatively: mutations are classified as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign.
Why Is a Liquidseq Breast & Ovarian Cancer Panel Done?
This test is requested when a doctor needs detailed molecular information about a patient's tumour genetics to guide diagnosis, treatment selection, or disease monitoring.
Common Symptoms That May Require This Test
A doctor may order this test when a patient presents with the following symptoms:
- A breast lump or noticeable mass in the breast
- Unexplained or persistent breast pain
- Abnormal nipple discharge
- Pelvic pain or pressure
- Abdominal bloating without a clear cause
- Changes in bowel or bladder habits
- Unexplained weight loss
Conditions This Test Can Help Detect
This panel can provide molecular information relevant to the following conditions:
- Breast cancer, including hereditary forms
- Ovarian cancer, including epithelial subtypes
- Treatment-resistant mutations in advanced cancers
- Actionable mutations that may qualify a patient for targeted therapies
- Minimal residual disease (cancer cells remaining after treatment)
- Disease recurrence after prior treatment
Liquidseq Breast & Ovarian Cancer Panel for Chronic Disease Monitoring
This test is well suited for ongoing monitoring in patients with active breast or ovarian cancer. By detecting tumour-derived DNA in the blood, it can track treatment response, identify signs of disease recurrence, and assess whether resistance mutations have developed. It is typically repeated at key treatment milestones or approximately every three to six months during active therapy.
How to Prepare and What to Expect
No special preparation is needed for this test, but a few practical steps will help ensure a smooth experience.
Do You Need to Fast?
No fasting is required before this test. There are no dietary restrictions to follow beforehand.
Practical Tips Before Your Test
Keep the following in mind before your appointment:
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test
- Inform your doctor about any recent chemotherapy, radiation, or blood transfusions, as these may affect results
- Carry a valid photo ID and a prescription from your oncologist
- Wear loose-fitting clothing that allows easy access to your arm
Step-by-Step Procedure
The Liquidseq Breast & Ovarian cancer panel involves the following steps:
- Arrive at the Lupin Diagnostics centre at your scheduled time with your clinical history and prescription.
- A trained phlebotomist will clean the collection site on your arm and draw approximately 10 ml of blood.
- The blood is collected into specialised Streck tubes designed to preserve cell-free DNA during transport.
- The sample is stored at 2°C to 8°C and sent to the laboratory for processing.
- In the laboratory, blood cells are separated from the plasma, and cell-free DNA is extracted from the plasma.
- The extracted DNA undergoes Next-Generation Sequencing (NGS), a method that reads the genetic code across all 93 genes in the panel.
Factors That Can Affect Accuracy
The following factors may influence the accuracy of your results:
- Low tumour burden (early-stage cancers shed less ctDNA into the bloodstream)
- Recent chemotherapy or radiation, which can temporarily alter ctDNA levels
- Improper tube handling, storage conditions, or insufficient sample volume
- Recent blood transfusion or bone marrow transplant, which may affect DNA analysis
Understanding Your Liquidseq Breast & Ovarian Cancer Panel Test Results
Results are qualitative and indicate whether specific gene mutations are present or absent. A specialist will review the findings alongside your clinical history and other investigations.
Result Classification
| Meaning | |
|---|---|
| No pathogenic variants detected | No cancer-related mutations identified in the genes tested |
| Pathogenic / Likely Pathogenic | A mutation associated with cancer risk or progression was found |
| Variant of Uncertain Significance (VUS) | A genetic change detected, but its clinical significance is not yet established |
| Likely Benign / Benign | Genetic variant unlikely to be associated with cancer |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain circumstances can affect how results should be read:
- In early-stage cancers, ctDNA levels in the blood are very low, which can reduce detection sensitivity. A negative result does not completely exclude the presence of cancer.
- Recent chemotherapy or radiation may temporarily reduce or alter ctDNA levels, affecting the interpretation of results.
- In rare cases such as bone marrow transplant or recent blood transfusion, the analysed DNA may not fully reflect the patient's own genome, which could lead to inaccurate results.
How to Maintain Healthy Levels
After receiving your results, the following general wellness steps are advisable:
- Attend all follow-up appointments with your oncologist and discuss next steps based on your findings.
- If hereditary mutations are identified, ask your doctor about genetic counselling for yourself and your family members.
- Follow a balanced diet and stay physically active as recommended by your healthcare team.
Lupin Diagnostics Liquidseq Breast & Ovarian Cancer Panel Price
The Liquidseq breast & ovarian cancer panel test cost starts at ₹72,000 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this test.
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 72000 |
| Pune | 72000 |
| Bangalore | 72000 |
| Chennai | 72000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book the Liquidseq breast & ovarian cancer panel online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
A tissue biopsy involves removing a small piece of tumour tissue for analysis. A liquid biopsy, by contrast, detects tumour DNA fragments circulating in your blood. It requires only a standard blood draw and avoids the discomfort associated with surgical tissue sampling.
This test is intended for patients with confirmed or suspected breast or ovarian cancer who need molecular profiling to guide treatment decisions. It is also useful for patients who cannot undergo a tissue biopsy or where tissue samples are insufficient for full analysis.
The report is delivered within 30 days of sample collection. NGS-based analysis is a detailed process that requires time for sequencing, data interpretation, and clinical reporting.
No. This test provides important molecular information but is not a standalone diagnostic tool. It is best used alongside clinical examination, imaging, and tissue biopsy where available. Your oncologist will interpret the findings as part of your complete clinical picture.
The panel covers 93 genes involved in breast and ovarian cancer biology, including ACVR1B, AKT1, APC, AR, ATM, ATR, BRCA1, BRCA2, TP53, PIK3CA, PTEN, ERBB2, ESR1, and many others. These genes are involved in DNA repair, tumour suppression, cell signalling, and hormone response.
This test primarily detects mutations in tumour-derived DNA. While inherited (germline) mutations may be picked up, the test cannot reliably distinguish between inherited and tumour-acquired mutations. If your doctor suspects a hereditary cancer syndrome, separate germline genetic testing may be recommended.
Yes. Clinical history is required for this test. Please bring a detailed summary of your symptoms, prior test results, treatment history, and family history of cancer when you visit the collection centre.
Liquidseq Breast & Ovarian Cancer Panel [93 genes]
